jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Fibroid small biopsy less than 1 cm

Biopsy
image

Report in 240Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Uterine fibroid histology.

₹296₹423

30% OFF

Fibroid Small Biopsy Less Than 1 cm - Comprehensive Medical Guide

  • Why is it done?
    • Tissue diagnosis of small uterine fibroids (leiomyomas) measuring less than 1 cm in diameter identified through imaging modalities
    • Differentiation between benign leiomyomas and other uterine lesions such as adenomyosis, polyps, or malignant tumors
    • Evaluation of incidentally discovered small nodules or masses during ultrasound, MRI, or hysteroscopic examination
    • Assessment of symptomatic patients presenting with abnormal uterine bleeding, pelvic pressure, or pain when small lesions are detected
    • Histological confirmation prior to therapeutic intervention or monitoring decisions
    • Typically performed when imaging findings are equivocal or when clinical symptoms warrant tissue-level diagnosis
  • Normal Range
    • Measurement: Less than 1.0 cm in greatest dimension by imaging
    • Normal Result: Benign smooth muscle tissue (leiomyoma) with characteristic histological features including interlacing smooth muscle bundles, absence of significant atypia, and normal mitotic activity (0-2 mitoses per 10 high-power fields)
    • Abnormal Result: Evidence of malignancy, atypical proliferation, significant nuclear atypia, increased mitotic activity (>5 mitoses per 10 HPF), or non-fibroid pathology (adenomyosis, endometrial carcinoma, sarcoma)
    • Units: Centimeters (cm) for lesion size; histological findings reported descriptively based on microscopic examination
    • Interpretation Categories:
    • Positive/Benign: Histologically confirmed leiomyoma without atypia or malignant features
    • Negative: Absence of fibroid tissue; other pathology identified (non-diagnostic for leiomyoma)
    • Atypical/Borderline: Features suggestive of leiomyosarcoma or other malignancy requiring urgent clinical correlation and specialist review
  • Interpretation
    • Benign Leiomyoma: Typical presentation showing well-demarcated smooth muscle bundles arranged in interlacing fascicles, uniform nuclei without significant enlargement or irregularity, scant mitotic activity (<2 per 10 HPF), no cellular atypia, and absence of necrosis. Clinical significance indicates benign tumor with low malignant potential
    • Mitotically Active Leiomyoma (MAL): Increased mitotic activity (5-9 mitoses per 10 HPF) without significant atypia or necrosis. Typically benign but may warrant closer clinical follow-up and monitoring given slightly elevated mitotic index
    • Atypical Leiomyoma: Presence of nuclear atypia (irregular nuclear membranes, hyperchromasia, variation in size) without increased mitoses or necrosis. Histologically uncertain malignant potential requiring close clinical surveillance
    • Leiomyosarcoma (LMS): Presence of significant nuclear atypia combined with increased mitotic activity (>10 per 10 HPF) and/or presence of tumor necrosis. Represents malignant diagnosis requiring urgent gynecologic oncology consultation and aggressive treatment planning
    • Non-fibroid Pathology: Identification of adenomyosis, endometrial polyp, endometrial carcinoma, or other uterine malignancy. Requires specific diagnostic and therapeutic management based on identified pathology
    • Factors Affecting Interpretation:
    • Specimen adequacy - insufficient tissue may preclude definitive diagnosis
    • Biopsy technique - core needle biopsies may have lower diagnostic yield than excisional specimens
    • Patient age and reproductive history - may influence interpretation of incidental findings
    • Clinical presentation - symptomatic vs. asymptomatic discovery affects management recommendations
    • Prior imaging findings - comparison with baseline studies aids in interpretation of changes
  • Associated Organs
    • Primary Organ System: Uterus (myometrium) - reproductive organ affected by benign and potentially malignant smooth muscle neoplasms
    • Common Benign Conditions:
    • Uterine leiomyomas (fibroids) - most common benign pelvic tumor in women of reproductive age
    • Adenomyosis - presence of endometrial tissue within myometrium
    • Endometrial polyps - benign projections from endometrial surface
    • Associated Malignant Conditions:
    • Uterine leiomyosarcoma (LMS) - rare malignant smooth muscle tumor arising de novo or rarely from pre-existing benign fibroid
    • Endometrial carcinoma - malignant tumor of endometrial origin
    • Uterine sarcomas - mesenchymal malignancies including carcinosarcoma and undifferentiated sarcoma
    • Common Clinical Presentations with Abnormal Results:
    • Abnormal uterine bleeding (menorrhagia, metrorrhagia) - associated with fibroids, adenomyosis, and endometrial pathology
    • Pelvic pain and dysmenorrhea - particularly with adenomyosis and submucosal fibroids
    • Pelvic pressure and mass effect - with larger fibroids potentially affecting bladder and bowel
    • Rapid uterine enlargement or rapid lesion growth - concerning for malignancy such as leiomyosarcoma
    • Potential Complications with Abnormal Results:
    • Leiomyosarcoma diagnosis - requires aggressive treatment including hysterectomy, staging, and possible adjuvant chemotherapy with poor prognosis
    • Endometrial cancer - requires comprehensive staging and multimodal therapy
    • Delayed diagnosis of malignancy - misdiagnosis of sarcoma as benign fibroid can result in delayed treatment
    • Secondary effects on adjacent organs - large lesions may compress bladder, bowel, or pelvic blood vessels
  • Follow-up Tests
    • If Benign Leiomyoma Confirmed:
    • Transvaginal or transabdominal ultrasound - baseline imaging for future comparison in symptomatic patients
    • MRI pelvis (if clinically indicated) - to assess full extent of uterine pathology and number of fibroids before planning intervention
    • Hysteroscopy - if submucosal component suspected or therapeutic intervention (resection) planned
    • Iron studies (ferritin, iron, TIBC) - if abnormal uterine bleeding documented to assess for iron deficiency anemia
    • If Atypical or Mitotically Active Leiomyoma:
    • Gynecologic pathology review - expert second opinion recommended given uncertain malignant potential
    • Serial imaging follow-up - repeat ultrasound or MRI at 3-month intervals to assess for rapid growth
    • Gynecologic oncology consultation - recommended if clinical concern for malignancy or rapid growth documented
    • If Leiomyosarcoma or Malignancy Identified:
    • Urgent gynecologic oncology consultation - within 1 week for treatment planning
    • Comprehensive staging studies: CT chest/abdomen/pelvis with IV contrast, CBC, comprehensive metabolic panel
    • MRI pelvis - for local staging and full extent of myometrial/uterine involvement
    • Tumor markers (if applicable) - LDH may be helpful for prognosis
    • Hysterectomy ± bilateral salpingo-oophorectomy - primary surgical treatment
    • Adjuvant chemotherapy consideration - doxorubicin-based regimens for advanced-stage disease
    • If Non-fibroid Pathology (Adenomyosis, Endometrial Carcinoma, Polyp):
    • Adenomyosis: Pelvic imaging reassessment; consider hysterectomy if symptomatic
    • Endometrial Carcinoma: Comprehensive endometrial cancer staging (imaging, tumor markers); gynecologic oncology referral for treatment planning
    • Endometrial Polyp: Hysteroscopic polypectomy if symptomatic or bleeding source; histological confirmation of tissue obtained
    • General Surveillance (Benign Confirmed):
    • Clinical assessment at routine gynecologic visits - annually or as symptoms warrant
    • Imaging reassessment only if change in symptoms or clinical indication
    • Symptom-directed management - medical therapy for abnormal bleeding or pain if desired
  • Fasting Required?
    • Fasting Required: No
    • Food and Beverage: Normal diet and hydration acceptable on day of procedure
    • Pre-procedure Preparation:
    • Imaging must be available prior to biopsy - ultrasound or MRI to localize lesion for accurate sampling
    • Timing of procedure - typically scheduled during follicular phase (first half of menstrual cycle) to minimize endometrial thickness and optimize visualization
    • Emptying of bladder - patient should void immediately prior to procedure (hysteroscopic approach) to reduce discomfort
    • Pelvic examination - patient may undress and be positioned on gynecologic examination table
    • Medications to Avoid:
    • Anticoagulants/Antiplatelet agents - discontinue aspirin, NSAIDs, warfarin, apixaban, rivaroxaban 3-5 days prior (in coordination with prescribing physician)
    • Herbal supplements - discontinue ginkgo, garlic, ginger, and other anticoagulant-type supplements 1 week prior
    • Anesthesia Considerations:
    • Office procedure with local anesthesia - typically no general anesthesia required for small biopsies
    • Pre-procedure medication - ibuprofen 600 mg 1 hour prior may be recommended for pain control
    • Topical/paracervical anesthesia - 1% lidocaine spray or local injection provided during procedure
    • Post-procedure Instructions:
    • Light spotting or bleeding may occur for 24-48 hours - use pads rather than tampons
    • Pelvic rest for 1-2 weeks - avoid douching, intercourse, tampon use, and strenuous exercise
    • Antibiotics - prophylactic antibiotics may be prescribed if high infection risk
    • Contact provider if fever, excessive bleeding, severe pain, or signs of infection develop

How our test process works!

customers
customers